Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biosyent Inc BIOYF


Primary Symbol: V.RX

Healthcare
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing... see more

Recent & Breaking News (TSXV:RX)

BioSyent to Attend Planet MicroCap Showcase

GlobeNewswire 8 days ago

BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement

GlobeNewswire April 15, 2024

BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 10, 2024

FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year

GlobeNewswire April 3, 2024

BioSyent to Present at LD Micro New York Investor Conference

GlobeNewswire April 1, 2024

BioSyent Announces Grant of Restricted Share Units

GlobeNewswire March 27, 2024

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023

GlobeNewswire March 13, 2024

BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024

GlobeNewswire March 6, 2024

BioSyent Named to 2024 TSX Venture 50

GlobeNewswire February 21, 2024

BioSyent Declares First Quarter 2024 Dividend

GlobeNewswire February 6, 2024

BioSyent Announces Renewal of Normal Course Issuer Bid

GlobeNewswire December 13, 2023

BioSyent Announces the Availability of Gelclair® in Canada

GlobeNewswire November 20, 2023

BioSyent Releases Q3 and YTD 2023 Financial Results

GlobeNewswire November 16, 2023

BioSyent Declares Fourth Quarter 2023 Dividend

GlobeNewswire November 15, 2023

BioSyent Schedules Q3 and YTD 2023 Earnings Release for November 16, 2023

GlobeNewswire November 9, 2023

BioSyent Launches "menopauseinformation.ca" on World Menopause Day

GlobeNewswire October 18, 2023

TSX Venture Exchange Stock Maintenance Bulletins

Canada NewsWire August 23, 2023

BioSyent Releases Q2 and H1 2023 Financial Results

GlobeNewswire August 22, 2023

BioSyent Declares Third Quarter 2023 Dividend

GlobeNewswire August 22, 2023

BioSyent Schedules Q2 and H1 2023 Earnings Release for August 22, 2023

GlobeNewswire August 15, 2023